The CHA2DS2-VASc score independently predicted the composite of non-fatal recurrent acute coronary syndrome and heart failure hospitalization (HR 1.26 per 1-point increment) in patients with ACS.
Cohort (n=2,213)
No
Does the CHA2DS2-VASc score predict recurrent ACS and heart failure hospitalization in patients following an acute coronary syndrome?
The CHA2DS2-VASc score is a useful clinical tool for predicting the risk of non-fatal recurrent ACS and heart failure hospitalization in patients who have survived an initial ACS event, independent of atrial fibrillation status.
Estimación del efecto: HR 1.26 (95% CI 1.11-1.44)
valor p: p=0.001
Abstract Recurrent acute coronary syndrome (ACS) and heart failure (HF) are the leading causes of readmission and are associated with a significantly worse prognosis than the original episode. This study aimed to assess the utility of the CHA 2 DS 2 -VASc score in predicting these events in patients with ACS. We enrolled 2,213 patients (1,603 men; mean age, 69 years) hospitalized for ACS who survived for 1 year after discharge. The primary outcome was the composite of non-fatal recurrent ACS and HF hospitalization. During the 12-month follow-up, the primary outcome was observed in 81 patients (3.7%), comprising 44 patients with recurrent ACS events and 37 with HF admissions. Multivariate Cox regression analyses revealed that the CHA 2 DS 2 -VASc score was an independent predictor of the primary outcome and HF admission, regardless of atrial fibrillation (AF) status, and included patients treated with primary percutaneous coronary intervention (PCI). The optimal CHA₂DS₂-VASc score cutoff value for predicting non-fatal events was 4 points. Integration of the CHA 2 DS 2 -VASc score with the N-terminal pro-B-type natriuretic peptide level improved the predictive accuracy for HF admission, as evidenced by higher C-index and net reclassification improvement values (both p < 0.05). In conclusion, the CHA 2 DS 2 -VASc score clearly identified high-risk patients based on recurrent ACS or admission for HF among those with ACS, irrespective of the presence of AF, and those undergoing primary PCI.
Sakaguchi et al. (Sat,) conducted a cohort in Acute Coronary Syndrome (n=2,213). CHA2DS2-VASc score was evaluated on Composite of non-fatal recurrent acute coronary syndrome and heart failure hospitalization (HR 1.26, 95% CI 1.11-1.44, p=0.001). The CHA2DS2-VASc score independently predicted the composite of non-fatal recurrent acute coronary syndrome and heart failure hospitalization (HR 1.26 per 1-point increment) in patients with ACS.